Physician profile

Stanley Nabrinsky

Hematology & Oncology · Elgin, IL

NPI 1568459774

$153,811.21

in general payments reported to CMS, 2019-2025

79 companies · $13K in 2025

The $13K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$26,048.75
Food and Beverage$9,989.23
Honoraria$9,200.00
Travel and Lodging$4,411.70
Long Term Medical Supply Or Device Loan$2,147.25
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$2,000.00
Education$718.87

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Genentech USA, INC. $29,859.85 2019-2025 Tecentriq, Alecensa, Venclexta
Astrazeneca Pharmaceuticals Lp $17,945.69 2019-2025 Imfinzi, Lynparza, Calquence
Blueprint Medicines Corporation $16,590.11 2021-2025 Ayvakit
Merck Sharp & Dohme LLC $11,978.50 2019-2025 Keytruda, Welireg, Lynparza
Emd Serono, INC. $10,981.54 2022-2024 Tepmetko, Bavencio
Agios Pharmaceuticals, INC. $6,945.79 2020-2025 Pyrukynd
Pfizer INC. $3,832.65 2019-2025
Janssen Biotech, INC. $3,354.43 2019-2025 Erleada, Rybrevant, Akeega
Novartis Pharmaceuticals Corporation $3,286.21 2019-2025
Epizyme, INC. $3,281.25 2022
Avyxa Pharma, LLC $3,060.07 2025
Taiho Oncology, INC. $3,037.13 2021-2024
Cti Biopharma Corp. $2,797.49 2022-2023 Vonjo
Beigene USA, INC. $2,663.08 2023-2024 Brukinsa
Takeda Pharmaceuticals U.S.A., INC. $2,609.85 2019-2025 Fruzaqla, Alunbrig, Iclusig
Show all 79 companies
CompanyGeneral paymentsYearsTop products
Coherus Oncology, INC. $2,300.00 2020-2021
Karyopharm Therapeutics INC. $2,036.81 2021-2025 Xpovio
Beone Medicines USA, INC. $1,950.00 2025
Glaxosmithkline, LLC. $1,901.30 2020-2025 Jemperli, Zejula, Ojjaara
Eisai INC. $1,640.71 2021-2025
Immunocore Limited $1,615.19 2022-2025 Kimmtrak
Celgene Corporation $1,565.88 2020-2025 Reblozyl, Pomalyst
Incyte Corporation $1,558.67 2021-2024 Monjuvi
Novocure INC. $1,310.00 2019
Rigel Pharmaceuticals, INC. $1,241.10 2022-2023 Rezlidhia, Tavalisse
Daiichi Sankyo INC. $1,228.72 2019-2025 Vanflyta, Enhertu
Puma Biotechnology, INC. $1,215.58 2019-2025
Abbvie INC. $1,200.07 2021-2025
Jazz Pharmaceuticals INC. $1,080.04 2025
E.R. Squibb & Sons, L.L.C. $993.10 2019-2024 Opdivo, Eliquis, Opdualag
Astellas Pharma US INC $959.52 2020-2025 Vyloy, Xtandi, Xospata
Eagle Pharmaceuticals, INC. $850.00 2022
Adaptive Biotechnologies Corporation $727.63 2020-2025 Clonoseq
Lilly USA, LLC $536.34 2019-2025 Verzenio
Beigene, Ltd. $450.00 2020
Janssen Pharmaceuticals, INC $428.47 2019-2024 Xarelto
Genzyme Corporation $413.82 2019-2025
Tempus Ai, INC $393.38 2024-2025 Xt Cdx
Pharmacosmos Therapeutics INC. $369.52 2022-2025 Monoferric, Cosela
Gilead Sciences, INC. $334.87 2021-2025 Trodelvy
Seagen INC. $304.07 2021-2023 Adcetris, Padcev, Tukysa
Sobi, INC $299.99 2024-2025
Cardinal Health 110 LLC $225.00 2020-2025
Tersera Therapeutics LLC $192.61 2023-2025 Xermelo, Zoladex
Modernatx, INC. $187.50 2022
Amgen INC. $175.83 2020-2025 Kyprolis
Regeneron Healthcare Solutions, INC. $136.81 2021-2024 Libtayo
Servier Pharmaceuticals LLC $133.10 2023-2025
Array Biopharma INC $128.01 2022-2025 Braftovi, Mektovi, Lorbrena
Biocon Biologics INC $112.83 2024-2025 Ogivri, Yesintek, Fulphila
Myriad Genetic Laboratories, INC. $111.14 2021-2023 Myrisk
Bayer Healthcare Pharmaceuticals INC. $102.46 2019-2024
Adc Therapeutics America, INC. $101.44 2022-2023
G1 Therapeutics, INC. $89.44 2022-2023 Cosela
Morphosys, US INC. $85.61 2022-2023 Monjuvi
Alexion Pharmaceuticals, INC. $79.99 2020-2025 Ultomiris
Exelixis INC. $79.50 2019
Pharmacyclics LLC, An Abbvie Company $77.67 2021-2022
Spectrum Pharmaceuticals INC. $67.58 2023-2024 Rolvedon
Secura Bio, INC. $63.84 2021
Deciphera Pharmaceuticals INC. $48.61 2023-2025 Qinlock, Romvimza
Accord Healthcare, INC. $47.85 2024-2025
Genmab U.S., INC. $43.83 2024-2025 Epkinly
Clovis Oncology, INC. $43.65 2021-2022
Aveo Pharmaceuticals, INC. $30.59 2023-2024 Fotivda
Progenics Pharmaceuticals, INC. $28.84 2025
Fennec Pharmaceuticals, INC. $28.75 2024 Pedmark
Mirati Therapeutics, INC. $27.99 2024 Krazati
Syndax Pharmaceuticals, INC. $25.76 2025
Myovant Sciences INC. $25.06 2022
Ge Healthcare $25.05 2024
Organon LLC $24.25 2023 Ontruzant
Mylan Institutional INC. $23.48 2023 Hulio
Azurity Pharmaceuticals, INC. $20.67 2025 Vivimusta, Danziten
Menarini Silicon Biosystems, INC. $20.04 2025
Verastem, INC. $19.94 2020
Immunogen, INC. $17.29 2023 Elahere
Kite Pharma, INC. $16.98 2022
Blue Earth Diagnostics $13.80 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stanley Nabrinsky

$153,811.21

in general payments reported 2019-2025

Years
2019-2025
Top company
Genentech USA, INC.
Context
The $13K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).

https://glasscript.com/doctor/116622/stanley-nabrinsky

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.